Key opinion leaders (KOLs) previously interviewed by GlobalData have noted that there is a significant unmet need for effective treatments for patients who are Musk+, LRP4+, or triple seronegative.
MG-ADL and QMG at 24 weeks, further increasing confidence in Phase 3 trial . Totality of efficacy and safety data re ...
Cemdisiran, an investigational small interfering RNA (siRNA) therapy targeting complement component 5 (C5), met both its ...
Clinically meaningful MG-ADL response (≥2-point reduction) occurred in 69% of treated patients, exceeding the 53% response rate observed in placebo comparators.
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease that causes muscle weakness that worsens with activity and often fluctuates throughout the day. Symptoms may include drooping ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results